The extracellular matrix on atherogenesis and diabetes-associated vascular disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Tamminen, 1999, Ultrastructure of early lipid accumulation in apoE-deficient mice, Arterioscler. Thromb. Vasc. Biol., 19, 847, 10.1161/01.ATV.19.4.847
Williams, 1995, The response-to-retention hypothesis of early atherogenesis, Arterioscler. Thromb. Vasc. Biol., 15, 551, 10.1161/01.ATV.15.5.551
Chait, 2000, Interaction of native and modified low-density lipoproteins with extracellular matrix, Curr. Opin. Lipidol., 11, 457, 10.1097/00041433-200010000-00003
von Eckardstein, 2000, Prevention of coronary heart disease by raising high-density lipoprotein cholesterol, Curr. Opin. Lipidol., 11, 627, 10.1097/00041433-200012000-00010
Lehto, 1997, Dyslipidemia and hyperglycemia predict coronary heart disease events in middleaged patients with NIDDM, Diabetes, 46, 1354, 10.2337/diabetes.46.8.1354
Wight, 1996, The vascular extracellular matrix, 421
Olsson, 1991, Molecular parameters that control the association of low density lipoprotein apoB-100 with chondroitin sulphate, Biochim. Biophys. Acta, 1097, 37, 10.1016/0925-4439(91)90021-Z
Olsson, 1993, Binding of a synthetic apolipoprotein B-100 peptide and peptide analogues to chondroitin 6-sulfate: effects of the lipid environment, Biochemistry, 32, 1858, 10.1021/bi00058a020
Camejo, 1998, Association of lipoproteins with arterial proteoglycans: pathological significance, Atherosclerosis, 139, 205, 10.1016/S0021-9150(98)00107-5
Chan, 1992, Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins, J. Biol. Chem., 267, 25621, 10.1016/S0021-9258(18)35646-1
Olsson, 1997, Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the apoB/E receptor, Arterioscler. Thromb. Vasc. Biol., 17, 149, 10.1161/01.ATV.17.1.149
Segrest, 1994, ApoB-100 has a pentapartite structure composed of three amphipathic α-helical domains alternating with two amphipathic β-strands domain: detection by the computer program domain, Arterioscler. Thromb. Vasc. Biol., 14, 1674, 10.1161/01.ATV.14.10.1674
Borén, 1998, Identification of the principal proteoglycan-binding site in LDL: a single point mutation in apoB-100 severely affects proteoglycan interaction without affecting LDL receptor binding, J. Clin. Invest., 101, 2658, 10.1172/JCI2265
Hurt-Camejo, 1990, Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages, J. Lipid Res., 31, 1387, 10.1016/S0022-2275(20)42610-0
McNamara, 1996, Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B, J. Lipid Res., 37, 1924, 10.1016/S0022-2275(20)37557-X
Borén, 2000, Role of extracellular retention of low density lipoproteins in atherosclerosis, Curr. Opin. Lipidol., 11, 451, 10.1097/00041433-200010000-00002
Packard, 1999, Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism, Curr. Opin. Lipidol., 10, 237, 10.1097/00041433-199906000-00006
Anber, 1997, Interaction of very-low-density, and low density lipoproteins with human arterial proteoglycans, Arterioscler. Thromb. Vasc. Biol., 17, 2507, 10.1161/01.ATV.17.11.2507
Wiklund, 1996, Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effect of lipid lowering drugs, Atherosclerosis, 119, 57, 10.1016/0021-9150(95)05628-9
Camejo, 1991, Modifications of low density lipoprotein induced by arterial proteoglycans and chondroitin-6-sulfate, Biochim. Biophys. Acta, 1096, 253, 10.1016/0925-4439(91)90013-Y
Sartipy, 1998, Phospholipase A2 type II binds to extracellular matrix byglycan: modulation of its activity on low density lipoproteins by co-localization in glycosaminoglycan matrixes, Arterioscler. Thromb. Vasc. Biol., 18, 1934, 10.1161/01.ATV.18.12.1934
Hurt-Camejo, 2000, Phospholipase A2 and small, dense low-density lipoprotein, Curr. Opin. Lipidol., 11, 465, 10.1097/00041433-200010000-00004
Schissel, 1996, Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein, J. Clin. Invest., 98, 1455, 10.1172/JCI118934
Hurt-Camejo, 1997, Potential involvement of type II phospholipase A2 in atherosclerosis, Atherosclerosis, 132, 1, 10.1016/S0021-9150(97)00085-3
Öörni, 2000, Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions, J. Lipid Res., 41, 1703, 10.1016/S0022-2275(20)31964-7
Hurt, 1990, Interaction of LDL with human arterial proteoglycans stimulates its uptake by humam monocyte-derived macrophages, J. Lipid Res., 31, 443, 10.1016/S0022-2275(20)43166-9
Vijayagopal, 1994, Regulation of the metabolism of lipoprotein–proteoglycan complexes in human monocyte derived macrophages, Biochem. J., 301, 675, 10.1042/bj3010675
Hurt-Camejo, 1992, Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells, Arterioscler. Thromb., 12, 569, 10.1161/01.ATV.12.5.569
Camejo, 1998, Hemin binding and oxidation of lipoproteins in serum:mechanisms and effect on the interaction of LDL with human macrophages, J. Lipid Res., 39, 755, 10.1016/S0022-2275(20)32564-5
Upritchard, 1999, Oxidation of heparin-treated low density lipoprotein by peroxidases, Atherosclerosis, 146, 211, 10.1016/S0021-9150(99)00127-6
Reaven, 1989, Measurement of plasma glucose free fatty acid, lactate and insulin for 24 h in patients with NIDDM, Diabetes, 37, 1020, 10.2337/diabetes.37.8.1020
Betteridge, 1997, Lipid disorders in diabetes mellitus
Ross, 1999, Atherosclerosis: an inflammatory disease, N. Engl. J. Med., 340, 115, 10.1056/NEJM199901143400207
Iozzo, 1998, Matrix proteoglycans: from molecular design to cellular function, Annu. Rev. Biochem., 67, 609, 10.1146/annurev.biochem.67.1.609
Lindblom, 1996, Basement membranes, 132
Ramasamy, 1993, Proteoglycans and endothelial barrier function:effect of linoleic acid exposure to porcine pulmonary artery endothelial cells, Atherosclerosis, 103, 279, 10.1016/0021-9150(93)90270-5
Mattock, 1998, Microalbuminuria and coronary heart disease in NIDDM, Diabetes, 47
Mykkänen, 1998, Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study, Diabetes, 47, 793, 10.2337/diabetes.47.5.793
Raats, 2000, Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria, Kidney Int., 57, 385, 10.1046/j.1523-1755.2000.00858.x
Comper, 1998, The glomerulus, 410
Jager, 1999, Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, specially among hypertensive subjects: five-year follow-up of the hoorn study, Arterioscler. Thromb. Vasc. Biol., 19, 617, 10.1161/01.ATV.19.3.617
Wasty, 1993, Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus, Diabetologia, 36, 316, 10.1007/BF00400234
Schmidt, 1990, Changes in heparan sulfate structure during transition from the proliferating to the non-dividing state of cultured arterial smmoth muscle cell, Eur. J. Cell Biol., 52, 229
Schönherr, 1991, Effects of platelet-derived growth factor and transforming growth factor b1 on the synthesis of large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cell, J. Biol. Chem., 266, 17640, 10.1016/S0021-9258(19)47419-X
Steele, 1987, Lipoprotein interaction with artery wall derived proteoglyvan. Comparisions between atherosclerosis-susceptible WC-2 and resistant Show Racer pigeons, Atherosclerosis, 65, 63, 10.1016/0021-9150(87)90008-6
Cardoso, 1994, Glycosaminoglycan fractions from human arteries presenting diverse susceptibilities to atherosclerosis have different binding affinities to plasma LDL, Arterioscler. Thromb., 14, 115, 10.1161/01.ATV.14.1.115
Camejo, 1993, Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells, J. Biol. Chem., 268, 14131, 10.1016/S0021-9258(19)85218-3
Edwards, 1995, Differentiated macrophages synthesize a heparan sulfate proteoglycan and a oversulfated chondroitin sulfate proteoglycan that bind lipoprotein lipase, Arterioscler. Thromb. Vasc. Biol., 15, 400, 10.1161/01.ATV.15.3.400
O'Brien, 1998, Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of byglycan with apolipoproteins, Circulation, 98, 519, 10.1161/01.CIR.98.6.519
Olsson, 1999, Fatty acids modulate the composition of extracellular matrix in cultured smooth muscle cells by altering the expression of genes for proteoglycan core proteins, Diabetes, 48, 616, 10.2337/diabetes.48.3.616
Vijayagopal, 1996, Marked alteration of proteoglycan metabolism in cholesterol-enriched human arterial smooth muscle cells, Biochem. J., 315, 995, 10.1042/bj3150995
Halvorsen, 1998, Proteoglycans in macrophages: characterization and possible role in the cellular uptake of lipoproteins, Biochem. J., 331, 743, 10.1042/bj3310743
Maor, 1999, Macrophage released proteoglycans are involved in cell-mediated aggregation of LDL, Atherosclerosis, 142, 57, 10.1016/S0021-9150(98)00191-9
Wight, 1999, Biosynthesis of proteoglycans, 161